CytoDyn closes $16.5 million private placement to fund leronlimab development
CYDY•Private placement closed to support leronlimab work
CytoDyn closed a USD 16.5 million financing in an unregistered placement to fund development of leronlimab.
Paulson Investment Company served as placement agent.
Proceeds are expected to fund operations into the second half of 2027.
Net proceeds are earmarked mainly for:
- clinical trials
- regulatory work
- data analysis
- manufacturing readiness
- compliance
- working capital
